Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas

Yoshida, Hiroyuki; Ishiko, Osamu; Sumi, Toshiyuki; Matsumoto, Yoshinari; Ogita, Sachio

doi:10.3892/ijo.19.3.537

Cited by 57 publications

(56 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, we could not find any difference in terms of TTP and OS according to either cytoplasmic or nuclear survivin status, in contrast with earlier studies which reported a negative prognostic role of survivin overexpression (Yoshida et al, 2001;Sui et al, 2002;Takai et al, 2002). However, it has to be taken into account that this is the first study examining the clinical relevance of survivin status in terms of clinical outcome in a single-institution large series of ovarian carcinomas, compared to previous reports which referred to very small sample series (Yoshida et al, 2001;Sui et al, 2002;Takai et al, 2002), sometimes biased by the inclusion of selected groups of patients (Yoshida et al, 2001).…”

Section: Discussioncontrasting

confidence: 99%

“…As far as the association between survivin and clinicopathological and surgical parameters is concerned, we showed that serous ovarian tumours expressed a significantly lower nuclear survivin content with respect to other histotypes, as also reported by Yoshida et al (2001). Moreover, an intriguing association between high expression of nuclear survivin and better chance of performing tumour cytoreduction at first surgery was shown, which is likely to be supported by the association of higher nuclear survivin content with the absence of distinctive patterns that usually preclude the feasibility of cytoreduction, such as tumour involvement of upper abdominal organs and mesentery (Fanfani et al, 2003).…”

Section: Discussionsupporting

confidence: 88%

“…Despite the availability of several studies exploring the expression of survivin protein in primary ovarian cancer, no definitive conclusions have been provided about its possible clinical role in this neoplasia (Yoshida et al, 2001;Sui et al, 2002;Takai et al, 2002; Cohen et al, 2003). As emphasised in Table 5, discrepancies among studies can be explained by size and clinical characteristics of the series examined (Yoshida et al, 2001;Sui et al, 2002;Takai et al, 2002;Cohen et al, 2003), as well as methodological differences: indeed, different antibodies as well as scoring systems for evaluation of survivin immunoreaction have been utilised.…”

Section: Discussionmentioning

confidence: 99%

“…As emphasised in Table 5, discrepancies among studies can be explained by size and clinical characteristics of the series examined (Yoshida et al, 2001;Sui et al, 2002;Takai et al, 2002;Cohen et al, 2003), as well as methodological differences: indeed, different antibodies as well as scoring systems for evaluation of survivin immunoreaction have been utilised. Moreover, survivin staining has been described as prevalent either in the cytoplasm (Yoshida et al, 2001;Takai et al, 2002;Zaffaroni et al, 2002) or in the nucleus (Sui et al, 2002;Takai et al, 2002;Cohen et al, 2003), and it has been not always clearly stated whether the overall rate of positivity was derived from a single subcellular compartment or both. We first separately describe the expression of survivin protein in cytoplasmic and nuclear compartments of ovarian tumour cells.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have attempted to delineate the clinical role of survivin expression in epithelial ovarian carcinomas but no definitive conclusions could be drawn probably because of the size and/or heterogeneity of the population series, incompleteness of clinical informations as well as the use of different antibodies and methods of score of survivin expression (Yoshida et al, 2001;Sui et al, 2002;Takai et al, 2002;Zaffaroni et al, 2002;Cohen et al, 2003).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters

et al. 2005

View full text Add to dashboard Cite

We investigated the association of survivin expression with prognosis and other apoptosis-related biological factors in 110 primary ovarian cancer patients admitted to the Division of Gynecologic Oncology, Catholic University of Rome. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections by using polyclonal antibody ab469 for survivin, and mouse monoclonal antibodies (clone 124 and DO-7), for bcl-2 and p53, respectively. Cytoplasmic survivin immunoreaction was observed in 84.5% cases, while nuclear survivin immunostaining was observed in 29.1% cases. We failed to find any relationship between cytoplasmic survivin positivity rate and any of the parameters examined. Serous tumours showed a lower percentage of nuclear survivin positivity with respect to other histotypes (20.5 vs 48.6%, respectively; P-value ¼ 0.004). The percentage of nuclear survivin positivity was higher in cases subjected to primary tumour cytoreduction (43.5%), with respect to patients subjected to exploratory laparotomy (20%) (P ¼ 0.024). Bcl-2 and p53 were, respectively, expressed in 27.3 and 60.0% of the cases and their expression was not correlated with survivin status. During the follow-up period, progression and death of disease were observed in 68 (61.8%) and 53 (48.2%) cases, respectively. There was no difference in time to progression and overall survival according to survivin status in ovarian cancer patients. In conclusion, in our experience, the immunohistochemical assessment of survivin status does not seem to be helpful in the prognostic characterisation of ovarian cancer. A more in depth investigation of the complex physiology of divergent survivin variants is needed in order to clarify the biological and the clinical role of differentially located survivin isoforms. (Hoskins et al, 2000), it is conceivable that the assessment of biochemical factors more strictly related to tumour cell biology and intrinsic aggressiveness could help identifying high-risk patients and facilitating management of this disease.Apoptosis (programmed cell death) has been proposed to play a role not only in cancer onset and progression but also in sustaining decreased tumour cell sensitivity to chemotherapy (Hickman, 1992;Thompson, 1995), which still represents one of the main prognostic indicators in this neoplasia (Hoskins et al, 2000). In this context, the analysis of the molecules possibly involved in the modulation of apoptosis seems to be particularly attractive.Survivin is a member of the inhibitors of apoptosis protein (IAP) family, which participates in the complex network regulating programmed cell death and also cell division (Ambrosini et al, 1997;Altieri and Marchisio, 1999;Salvesen and Duckett, 2002). Survivin protein is commonly detected in fetal tissues but not in normal adult tissues, while being overexpressed in human cancer, thus suggesting the contribution of survivin gene reactivation in carcinogenesis (Ambrosini et al, 1997). The crucial role of survivin in protection from apoptosis is supported by the o...

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters

et al. 2005

View full text Add to dashboard Cite

show abstract

Expression of survivin in astrocytic tumors

Kajiwara

Yamasaki

Hama

et al. 2003

Cancer

131

View full text Add to dashboard Cite

BACKGROUNDAstrocytic tumors are the most common tumors of the central nervous system. The mechanisms of genetic change of astrocytic tumors have not been understood completely. Recently, survivin has been identified as a member of the inhibitor‐of‐apoptosis family. Survivin expression is considered an important prognostic factor of many tumors.METHODSThe authors investigated 43 astrocytic tumors (8 diffuse astrocytomas; 15 anaplastic astrocytomas; 20 glioblastomas). The authors examined survivin mRNA expression in tumor specimens by reverse transcriptase‐polymerase chain reaction amplification. The authors analyzed the relationship between survivin expression and other molecular changes commonly found in astrocytic tumors [p53 alteration, overexpression of epidermal growth factor receptor (EGFR), and bcl‐2 expression].RESULTSThirty‐four of 43 (79.1%) astrocytic tumors expressed survivin. The distributions included 3 of 8 (37.5%) diffuse astrocytomas, 13 of 15 (86.7%) anaplastic astrocytomas, and 18 of 20 (90.0%) glioblastomas. Expression of survivin (P = 0.0057) and EGFR (P = 0.0112) was significantly associated with malignant grade of astrocytic tumors, but expression of p53 (P = 0.1893) and bcl‐2 (P = 0.2552) was not. Furthermore, patients with survivin‐positive astrocytic tumors had significantly shorter overall survival times compared with patients who had survivin‐negative tumors (P = 0.0271).CONCLUSIONSSurvivin expression in astrocytic tumors varies with histologic malignancy and may play an important role in the oncogenesis and progression of astrocytic tumors. These data suggest that survivin has great potential as a therapeutic target in astrocytic tumors. Cancer 2003;97:1077–83. © 2003 American Cancer Society.DOI 10.1002/cncr.11122

show abstract

Survivin study: What is the next wave?

2003

Journal Cellular Physiology

287

288

View full text Add to dashboard Cite

Survivin, a novel member of inhibitor of apoptosis (IAP) protein family, is aberrantly expressed in cancer but undetectable in normal, differentiated adult tissues. Current studies suggest that survivin is implicated in both control of apoptosis and regulation of cell division. However, due to some inconsistent observations on survivin subcellular localization, there is debate about survivin's function in regulating apoptosis, cell division, or both. This review will discuss concepts, experimental methods, and interesting results that unify the different notions about survivin localization and function or point out gaps of knowledge about controversial issues. The author also intends to review various aspects of survivin studies, which were not emphasized or sufficiently discussed in previous reviews on survivin, and update recent developments that may reveal new applications of disease-oriented therapeutics in the coming years.

show abstract

Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas

Cited by 57 publications

References 0 publications

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters

Expression of survivin in astrocytic tumors

Survivin study: What is the next wave?

Contact Info

Product

Resources

About